Drug Delivery, Filler and Protein - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Drug Delivery

Filler

Protein

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

NOVEMBER 4, 2020

It is the first such project in China to develop recombinant mussel adhesive protein by gene recombination, fermentation engineering technology and specific enzyme catalytic fusion technology, and is expected to become a leader in this field. For additional information, please visit [link].

Licensing

Licensing Licensing Dermatology Production

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

The Pharma Data

DECEMBER 27, 2020

Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. About TLC599. An in vivo toxicity study by staining of the cartilage showed TLC599 to be cartilage sparing compared to current treatments.

Trials

Trials Clinical Trials Clinical Trials Containment

Crescita Announces Licensing Agreement for Pliaglis; in China

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

Stay Connected